Published in Mol Pharm on January 08, 2016
Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol (2001) 11.41
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
EGFR and cancer prognosis. Eur J Cancer (2001) 7.52
Structure of the δ-opioid receptor bound to naltrindole. Nature (2012) 3.69
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res (1992) 3.66
Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev (2003) 2.92
Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A (2004) 2.77
Integrins: roles in cancer development and as treatment targets. Br J Cancer (2004) 2.76
Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63
Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med (1999) 2.62
Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med (1995) 2.45
Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol (1988) 2.18
Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 2.02
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol (1995) 1.84
Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget (2012) 1.67
Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Anal Biochem (2004) 1.66
Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev (2008) 1.58
Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull (2001) 1.53
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A (2006) 1.52
Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab (2000) 1.49
Membrane recycling and epithelial cell function. Am J Physiol (1989) 1.46
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
Peptide-based probes for targeted molecular imaging. Biochemistry (2010) 1.43
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem (2002) 1.40
Autofluorescence of living cells. J Microsc (1998) 1.39
Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem (2005) 1.38
Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med (1995) 1.34
Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol (1997) 1.27
Development of a lanthanide-based assay for detection of receptor-ligand interactions at the delta-opioid receptor. Anal Biochem (2005) 1.25
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem (1988) 1.25
Enhanced targeting with heterobivalent ligands. Mol Cancer Ther (2009) 1.21
Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol (2009) 1.21
Role of phospholipids in endocytosis, phagocytosis, and macropinocytosis. Physiol Rev (2013) 1.19
Gold nanorods targeted to delta opioid receptor: plasmon-resonant contrast and photothermal agents. Mol Imaging (2008) 1.15
Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther (1991) 1.09
Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. J Med Chem (1997) 1.05
Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide "OA02". Mol Imaging (2005) 1.04
Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate (1989) 1.03
Role of folate receptor genes in reproduction and related cancers. Front Biosci (2006) 1.02
Recent advances in receptor-targeted fluorescent probes for in vivo cancer imaging. Curr Med Chem (2012) 1.02
Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One (2011) 1.01
Cell-specific targeting by heterobivalent ligands. Bioconjug Chem (2011) 1.00
Evaluation of receptors for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab (1990) 0.99
Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst (1987) 0.99
G protein independent phosphorylation and internalization of the delta-opioid receptor. J Neurochem (2009) 0.97
Angiogenic potential of microvessel fragments is independent of the tissue of origin and can be influenced by the cellular composition of the implants. Microcirculation (2010) 0.96
Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells. Br J Pharmacol (2003) 0.95
Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc Natl Acad Sci U S A (2012) 0.94
High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy. Pediatr Res (1999) 0.91
Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org Lett (2009) 0.90
Selective naltrexone-derived opioid receptor antagonists. Annu Rev Pharmacol Toxicol (1992) 0.90
The role of tumor tissue architecture in treatment penetration and efficacy: an integrative study. Front Oncol (2013) 0.88
Epidermal growth factor receptor and bladder cancer: a review. Urol Int (1992) 0.87
delta-Opioid receptor-stimulated Akt signaling in neuroblastoma x glioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation. Exp Cell Res (2009) 0.87
An optical probe for noninvasive molecular imaging of orthotopic brain tumors overexpressing epidermal growth factor receptor. Mol Cancer Ther (2012) 0.86
Opioid peptides in cancer. Cancer Metastasis Rev (2004) 0.84
Relative efficacies of delta-opioid receptor agonists at the cloned human delta-opioid receptor. Eur J Pharmacol (1997) 0.82
The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors. Eur J Pharmacol (2006) 0.82
Direct effects of delta opioid receptor agonists on invasion-associated activities of HCT-8/E11 colon cancer cells. Anticancer Res (2010) 0.80
Molecular characterization of the human delta opioid receptor in lung cancer. Anticancer Res (1998) 0.80
Upregulation of the δ opioid receptor in liver cancer promotes liver cancer progression both in vitro and in vivo. Int J Oncol (2013) 0.80
Inhibition of δ-opioid receptors induces brain glioma cell apoptosis through the mitochondrial and protein kinase C pathways. Oncol Lett (2013) 0.79
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med (2007) 8.28
Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res (2009) 3.40
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng (2005) 1.78
High-temperature piezoelectric sensing. Sensors (Basel) (2013) 1.70
Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol (2010) 1.50
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res (2008) 1.48
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res (2009) 1.42
Imaging the extracellular pH of tumors by MRI after injection of a single cocktail of T1 and T2 contrast agents. NMR Biomed (2011) 1.40
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica (2012) 1.39
Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res (2012) 1.38
Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS One (2011) 1.36
Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl (2008) 1.36
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Test-retest reliability of a sexual behavior interview for men residing in Brazil, Mexico, and the United States: the HPV in Men (HIM) Study. Am J Epidemiol (2009) 1.33
Trends in internal hernia incidence after laparoscopic Roux-en-Y gastric bypass. Obes Surg (2007) 1.29
Enhanced targeting with heterobivalent ligands. Mol Cancer Ther (2009) 1.21
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant (2010) 1.21
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med (2013) 1.19
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer (2008) 1.15
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol (2011) 1.14
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res (2006) 1.12
High-throughput sequencing of peptoids and peptide-peptoid hybrids by partial edman degradation and mass spectrometry. J Comb Chem (2009) 1.11
Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clin Cancer Res (2011) 1.10
Enhanced imaging and accelerated photothermalysis of A549 human lung cancer cells by gold nanospheres. Nanomedicine (Lond) (2008) 1.10
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10
The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica (2011) 1.10
MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol (2009) 1.07
Real-time noninvasive imaging of fatty acid uptake in vivo. ACS Chem Biol (2012) 1.06
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol (2010) 1.04
A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers (2013) 1.03
Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One (2011) 1.01
Exploring disparities and variability in perceptions and self-reported colorectal cancer screening among three ethnic subgroups of U. S. Blacks. Oncol Nurs Forum (2010) 1.01
A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. Cancer Res (2010) 1.01
Small-bowel obstruction after laparoscopic Roux-en-Y gastric bypass: etiology, diagnosis, and management. Arch Surg (2007) 0.99
Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Hum Vaccin Immunother (2013) 0.98
Test-retest reproducibility analysis of lung CT image features. J Digit Imaging (2014) 0.98
Molecular and functional imaging of breast cancer. Cancer Control (2010) 0.96
Osteopontin identified as colon cancer tumor progression marker. C R Biol (2004) 0.96
HAS1 expression in bladder cancer and its relation to urinary HA test. Int J Cancer (2007) 0.95
Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure. Obes Surg (2008) 0.95
Free Base Lysine Increases Survival and Reduces Metastasis in Prostate Cancer Model. J Cancer Sci Ther (2011) 0.94
Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc Natl Acad Sci U S A (2012) 0.94
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol (2010) 0.93
Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood (2013) 0.91
Improved survival modeling in cancer research using a reduced piecewise exponential approach. Stat Med (2013) 0.91
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.90
Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res (2012) 0.90
Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org Lett (2009) 0.90
Photoacoustic tomography and fluorescence molecular tomography: a comparative study based on indocyanine green. Med Phys (2012) 0.90
A sucrose-derived scaffold for multimerization of bioactive peptides. Bioorg Med Chem (2011) 0.90
Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors. Bioorg Med Chem (2013) 0.89
Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. J Med Chem (2011) 0.89
Synthesis and characterization of a Eu-DTPA-PEGO-MSH(4) derivative for evaluation of binding of multivalent molecules to melanocortin receptors. Bioorg Med Chem Lett (2010) 0.89
Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity. J Urol (2006) 0.89
Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. Breast J (2013) 0.88
Male breast cancer: management and follow-up recommendations. Breast J (2011) 0.88
The role of tumor tissue architecture in treatment penetration and efficacy: an integrative study. Front Oncol (2013) 0.88
Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.87
Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 0.87
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A (2013) 0.87
Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Subcell Biochem (2014) 0.86
Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Transplant (2010) 0.85
HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res (2006) 0.85
Demonstration of a sucrose-derived contrast agent for magnetic resonance imaging of the GI tract. Bioorg Med Chem Lett (2013) 0.85
Anastomotic leak or organ space surgical site infection: What are we missing in our quality improvement programs? Surgery (2013) 0.84
Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. Stat Biopharm Res (2012) 0.84
The promise of nanotechnology for solving clinical problems in breast cancer. J Surg Oncol (2011) 0.83
Cholecystectomy during laparoscopic gastric bypass has no effect on duration of hospital stay. Obes Surg (2007) 0.82
Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. Bioconjug Chem (2012) 0.82
Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy. J Med Chem (2012) 0.81
In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. Mol Pharm (2013) 0.81
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol (2011) 0.81
Radiological findings in symptomatic internal hernias after laparoscopic gastric bypass. Obes Surg (2009) 0.81
CT scan diagnosis of bleeding peptic ulcer after gastric bypass. Obes Surg (2007) 0.81
Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma (2013) 0.81
Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant (2009) 0.80
Hysterotomy for retained placenta in a septate uterus: a case report. Case Rep Obstet Gynecol (2012) 0.80
Intracellular electric field and pH optimize protein localization and movement. PLoS One (2012) 0.80
Development and in vivo quantitative magnetic resonance imaging of polymer micelles targeted to the melanocortin 1 receptor. J Med Chem (2013) 0.79
Photocatalysis by tetraphenylporphyrin of the decomposition of chloroform. Photochem Photobiol Sci (2008) 0.79
Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant (2010) 0.79